Search the Newsreel

Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts

Keros Therapeutics (NASDAQ:KROS) has received an average "Hold" rating from analysts, with nine analysts providing coverage: four buy, three hold, and two sell recommendations. The average 12-month price target is $20.50, significantly higher than its current $11.15 price. Despite this, the company reported weaker-than-expected …

Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen

Wall Street Zen has upgraded Keros Therapeutics (NASDAQ:KROS) from a "strong sell" to a "sell" rating, while other analysts remain divided with a consensus "Hold" rating and an average price target of $20.50. The company reported a Q2 EPS of -$1.45, missing estimates, and …

Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS

Renaissance Technologies LLC has reduced its stake in Keros Therapeutics, Inc. by 23.4%, selling 138,204 shares and now owning 453,482 shares valued at approximately $5.0 million. This comes as Keros shares trade near their 52-week low, following a quarterly loss that missed analyst estimates …

FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst

HC Wainwright has revised its FY2026 EPS estimate for Keros Therapeutics (NASDAQ:KROS), forecasting a smaller loss of $4.62 per share, an improvement from their previous estimate of a $5.12 loss. Despite this, the company faces mixed analyst sentiment with a consensus "Hold" rating and …

KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus

Keros Therapeutics (KROS) reported a Q2 2026 loss of $1.45 per share, wider than anticipated, with revenues falling to zero as the company has no marketed product. Despite the lack of revenue, Keros maintains a cash runway into the first half of 2028, supporting …

TD Cowen Maintains Keros Therapeutics(KROS.US) With Hold Rating

TD Cowen has reiterated its Hold rating on Keros Therapeutics (KROS.US). The article does not provide further details or a price target for the stock.

Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.33, Implies 101% Upside

Keros Therapeutics, Inc.'s stock average price target has been reduced from $21.83 to $20.33 by 6 analysts, with a range of $16 to $25 per share. This new target suggests a potential 101% upside based on the August 3 closing price. The consensus rating …

Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings, reporting a loss of $1.45 per share, which missed the consensus estimate by $0.20. The company also posted negative returns on equity and net margin. KROS shares are trading near their one-year low, and analysts maintain a …

Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23

Leerink Partners has reiterated its Buy rating for Keros Therapeutics (KROS.US) but has lowered its target price to $23. This adjustment reflects the firm's updated valuation for the biopharmaceutical company.

Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners

Leerink Partners has lowered its price target for Keros Therapeutics (NASDAQ:KROS) to $23.00 from $30.00, while maintaining an "outperform" rating, suggesting a potential upside of 127.5% from its previous close. The company recently missed consensus earnings estimates, reporting a quarterly loss of $1.45 per …

Keros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary

Keros Therapeutics reported zero revenue and a net loss of ($28.71M) for the 2026 quarter, resulting in a diluted EPS of ($1.45). This decline is attributed to a transition of partnered activities to Takeda, which also led to reduced R&D and G&A spending. The …

Keros Therapeutics posts $28.7 million second quarter net loss

Keros Therapeutics (KROS) reported a Q2 2026 net loss of $28.7 million, an improvement from a $30.7 million loss in Q2 2025, with no total revenue for the quarter. The company initiated a Phase 2 clinical trial for rinvatercept and expects initial data in …

Keros Therapeutics Reports Second Quarter 2026 Financial Results

Keros Therapeutics announced its Q2 2026 financial results, reporting a net loss of $28.7 million, an improvement from $30.7 million in Q2 2025. The company also provided a business update, including the initiation of a Phase 2 clinical trial for rinvatercept in Duchenne muscular …

Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research

Zacks Research has downgraded Keros Therapeutics (NASDAQ:KROS) to a "strong sell" rating, citing weaker-than-expected quarterly results where the company missed both earnings per share and revenue estimates. The stock is trading near its 52-week low, and company insiders have recently sold a significant amount …

Keros Therapeutics to Receive $20M Development Milestone Payment From Takeda

Keros Therapeutics is set to receive a $20 million development milestone payment from Takeda Pharmaceutical Company. This payment follows Takeda's decision to advance one of Keros's novel investigational compounds into a Phase 1 clinical trial for the treatment of a rare hematological disease. The …

Keros Therapeutics Inc (KROS) Institutional Confidence

Keros Therapeutics Inc (KROS) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 16.94% quarter-over-quarter, reaching 114.30%. James Simons is the largest institutional shareholder, holding 2.30% of outstanding shares.

Keros Therapeutics to Receive $20M Milestone After First ELRiSE MDS Patient Dosed

Keros Therapeutics is set to receive a $20 million milestone payment from Takeda after the first patient was dosed in the Phase 3 ELRiSE MDS trial. This payment is part of a larger global license agreement that included a $200 million upfront payment and …

Keros expects to distribute 25% of net cash proceeds after Takeda payment

Keros Therapeutics will receive a $20 million development milestone payment from Takeda, triggered by the first patient dosing in the Phase 3 ELRiSE MDS trial for elritercept. This payment is part of a global license agreement that includes a prior $200 million upfront payment …

BlackRock (KROS holder) discloses 1.67M-share, 8.4% stake in Keros Therapeutics

BlackRock, Inc. has disclosed a beneficial ownership stake of 8.4% in Keros Therapeutics, Inc. (KROS), totaling 1,671,343 shares of common stock as of June 30, 2026. The filing indicates BlackRock holds sole voting power over 1,645,352 shares and sole dispositive power over all 1,671,343 …

Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday

Keros Therapeutics (KROS) is expected to report its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts forecasting a loss of $1.25 per share and revenue of $807,000. This follows its previous quarter where the company missed expectations, reporting a $1.21 …

Kross Limited schedules virtual analyst meet for July 29

Keros Therapeutics Inc (KROS) Financial Health: Profitability & Balance Sheet Analysis

Keros Therapeutics Inc (KROS) has a financial score of 6.25, placing it 274th out of 386 in the Biotechnology & Medical Research industry, indicating a robust financial status despite low operating efficiency. The company's latest quarterly revenue decreased by 99.83% year-over-year, and its net …

Keros Therapeutics Inc (KROS) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Keros Therapeutics Inc (KROS) focusing on its dividend and stock split history. It states that Keros Therapeutics has not distributed any dividends over the past five years and contains no data regarding historical payouts or event timelines. Financial …

Keros Therapeutics Inc (KROS) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides a detailed breakdown of Keros Therapeutics Inc (KROS) shareholder structure, listing major shareholders and their proportional holdings. It also outlines the types of shareholders, institutional shareholding trends over several quarters, and recent shareholder activity with changes in holdings for key investors. …

Kross Ltd Q4 Results: Earnings call audio uploaded for Q4FY26 review

Keros Therapeutics Inc (KROS) Cash Flow

This article provides the cash flow statements for Keros Therapeutics Inc (KROS), including operating, investing, and financing activities, presented in both quarterly and annual formats. It details various components of cash flow, such as net income, changes in working capital, capital expenditures, and stock …

Keros Therapeutics, Inc. Revenue Breakdown – NASDAQ:KROS

Keros Therapeutics, Inc. (NASDAQ: KROS) generated $244.06 million USD in revenue last year, primarily from its Novel Therapeutics segment. This marks a significant increase from $3.55 million USD in the previous year. The United States was the greatest contributor to its revenue.

Kross Limited sets Sept 16 date for 35th AGM; approves FY25-26 report

KROS|Keros Therapeutics Inc|Price:10.060|Chg%:-0.080

Keros Therapeutics Inc. (KROS) is currently trading at $10.06, down 0.79%, with a market cap of $198.51M. The company, a clinical-stage biopharmaceutical firm, focuses on developing therapeutics for disorders linked to dysfunctional TGF-B signaling. Analysts currently rate KROS as "Buy" with a target price …

Kross Limited Reports Q1 FY27 Net Profit of ₹13.31 Crore, Up 24.4% YoY; Revenue Reaches ₹184.34 Crore

Kross to Hold Board Meeting Tomorrow; Shares Declined 0.25 percent

Keros Therapeutics CFO Keith Regnante resigns effective Aug. 3

Keros Therapeutics announced that its Chief Financial Officer, Keith Regnante, has resigned, with his departure effective August 3. Annita Tanini, the current Vice President of Finance, has been appointed as the interim principal financial officer to maintain continuity. This leadership transition was disclosed in …

Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head

Keros Therapeutics (NASDAQ: KROS) has announced that its Chief Financial Officer, Keith Regnante, will resign effective August 3, 2026. Annita Tanini, currently Corporate Controller and Vice President, Finance, has been appointed interim principal financial and accounting officer starting August 4, 2026, while the company …